Creative Medical Technology Holdings, Inc. announced promising one-year follow-up data from its AlloStem™ (CELZ-201) Type 2 Diabetes pilot study for late-stage patients. CELZ-201 is a proprietary allogenic (donor) cell line developed by the company. The results demonstrated an 80% overall efficacy rate in reducing insulin dependency and stabilizing hemoglobin A1c levels.
The study, which included 20 patients, with 10 receiving CELZ-201 and 10 undergoing optimized medical therapy, reported no serious adverse effects. This absence of safety concerns further supports the potential of CELZ-201 as a breakthrough treatment for late-stage Type 2 Diabetes. The infusion procedure used was the same as in the company’s U.S. FDA-cleared Type 1 Diabetes clinical trial.
Given these compelling results, Creative Medical Technology plans to advance the development of AlloStem (CELZ-201) for late-stage Type 2 Diabetes and explore other potential applications. This program aims to revolutionize diabetes treatment for a wide variety of patients who may not benefit from autologous therapies, addressing a condition that affects approximately 90-95% of the 38 million Americans diagnosed with diabetes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.